{"id":"NCT01289028","sponsor":"Novartis Pharmaceuticals","briefTitle":"Efficacy of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Imatinib and Sunitinib.","officialTitle":"An Open-label, Multi-center Study to Evaluate the Efficacy of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Imatinib and Sunitinib.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-11","primaryCompletion":"2014-07","completion":"2014-07","firstPosted":"2011-02-03","resultsPosted":"2016-11-01","lastUpdate":"2017-01-02"},"enrollment":125,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Gastrointestinal Stromal Tumors"],"interventions":[{"type":"DRUG","name":"Nilotinib","otherNames":["AMN107"]}],"arms":[{"label":"Nilotinib","type":"EXPERIMENTAL"}],"summary":"This study will evaluate the preliminary efficacy of nilotinib in pretreated patients (Imatinib, Sunitinib) with unresectable or metastatic gastrointestinal stromal tumors.","primaryOutcome":{"measure":"Percent of Patients Achieving Stable Disease (SD)","timeFrame":"During the first 4 months","effectByArm":[{"arm":"Nilotinib","deltaMin":48.8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":19,"countries":["Germany","Italy"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":60,"n":125},"commonTop":["Fatigue","Constipation","Abdominal pain","Nausea","Vomiting"]}}